Citations

Showing 10 of 108094 citations.

Image Analysis Software as a Strategy to Improve the Radiographic Determination of Fracture Healing
Duryea, J. , Evans, Christopher H. , Glatt, Vaida , Evans, Christopher

Mayo Clinic

Journal of Orthopaedic Trauma | June 10, 2018 | Volume: 32 | Issue: 9 | Pages: e354-e358

10.1097/bot.0000000000001234 | PMID 29889824 Get It

Objectives: To develop and validate an unbiased, accurate, convenient, and inexpensive means of determining when an osseous defect has healed and recovered sufficient strength to allow weight bearing. Methods: A novel image processing software algorithm was created to analyze the radiographic images and produce a metric designed to reflect the bone strength. We used a rat femoral segmental defect model that provides a range of healing responses from complete union to nonunion. Femora were examined by x-ray, micro–computed tomography and mechanical testing. Accurate simulated radiographic images at different incident x-ray beam angles were produced from the micro–computed tomography data files. Results: The software-generated metric (SC) showed high levels of correlation with both the mechanical strength (τMech) and the polar moment of inertia (pMOI), with the mechanical testing data having the highest association. The optimization analysis yielded optimal oblique angles θB of 125 degrees for τMech and 50 degrees for pMOI. The Pearson R2 values for the optimized model were 0.71 and 0.64 for τMech and pMOI, respectively. Further validation using true radiographs also demonstrated that the metric was accurate and that the simulations were realistic. Conclusions: The preliminary findings suggest a very promising methodology to assess bone fracture healing using conventional radiography. With radiographs acquired at appropriate incident angles, it proved possible to accurately calculate the degree of healing and the mechanical strength of the bone. Further research is necessary to refine this approach and determine whether it translates to the human clinical setting.
The Yips: Methods to Identify Golfers with a Dystonic Etiology/Golfer’s Cramp
Adler, Charles H., TEMKIT, M’HAMED, Crews, Debra J., McDaniel, Troy , Tucker, Jennifer, Hentz, Joseph G. , Marquardt, Christian , Abraham, Dale, Caviness, John N.

Mayo Clinic

Medicine & Science in Sports & Exercise | June 10, 2018 | Volume: 50 | Issue: 11 | Pages: 2226-2230

10.1249/mss.0000000000001687 | PMID 29889820 Get It

ABSTRACT Purpose To determine whether quantitative methods could separate golfers with a possible dystonic cause of the “yips” from those that appear to be nondystonic. Methods Twenty-seven golfers completed 10 two-handed and 10 right hand–only putts. Surface EMG assessed forearm muscle co-contraction and motion detectors monitored wrist and putter movements. Based on a videotape review, golfers were grouped into those with yips of dystonic etiology, those with the yips nondystonic, and those with no yips. Results On video review of two-handed putting, five golfers had yips that appeared to be dystonic, nine had yips that did not appear to be dystonic, and 13 had no yips. During two-handed putting co-occurrence of a yipped putt and wrist flexor/extensor and/or pronator/supinator co-contraction was significantly more frequent in those with dystonic yips. The dystonic group had no increase in the number of yipped putts or yips with co-contraction when putting right hand only, whereas the nondystonic group had significantly more yipped putts and more yipped putts with co-contraction with right hand only. Conclusions Quantitative methods were identified that appear to identify golfers with a dystonic etiology for the yips. It is not just the frequency of yips nor just specific motion patterns alone, rather it is also a combination of yips with co-occurring co-contraction when putting with two hands, and then right hand only, that distinguished this possible etiology. Despite being a small study, identifying a dystonic pattern, even in a nonpressure indoor setting, may aid in assessment and possible monitoring of treatment.
Postexercise Hemodynamic Responses in Lean and Obese Men
Zeigler, Zachary , Swan, Pamela D. , Buman, Matthew P. , Mookadam, Farouk , Angadi, Siddhartha S. , Mookadam, Farouk , Gaesser, Glenn A. , Buman, M. P.

Mayo Clinic

Medicine & Science in Sports & Exercise | June 10, 2018 | Volume: 50 | Issue: 11 | Pages: 2292-2300

10.1249/mss.0000000000001684 | PMID 29889821 Get It

ABSTRACT Purpose We assessed resting central/peripheral blood pressure (BP), postexercise BP, and hemodynamic responses (stroke volume, cardiac output, and systemic vascular resistance) after acute exercise and 2 wk of aerobic training in lean and centrally obese men matched for BP. Methods Eight lean (body mass index < 25 kg·m −2 , visceral fat = 279 ± 224 cm 3 ) and eight centrally obese (body mass index > 30 kg·m −2 , visceral fat = 1471 ± 374 cm 3 ) men performed six training sessions (3 d·wk −1 for 40 min at 65%–70% HR max ). Resting BP and hemodynamic measurements were obtained at baseline, after exercise for 60 min, and at 24 h and 48 h after the last training session. Results Postexercise brachial and central systolic BP (SBP) and mean arterial BP decreased 3–4 mm Hg below resting in lean ( P < 0.001) and increased by 3 mm Hg in obese ( P < 0.02). Posttraining resting brachial/central SBP were reduced by 3–4 mm Hg only in lean men ( P < 0.05). Pretraining postexercise hypotension was significantly correlated with the training-induced change in resting brachial SBP at 48 h ( r = 0.58, P = 0.02), but not at 24 h ( r = 0.38, P = 0.15). Similar correlations were observed between acute reductions in central SBP and central SBP at 24 h ( r = 0.43, P = 0.09) and 48 h ( r = 0.54, P = 0.03) posttraining. Conclusions In contrast to the consistent results for lean men, postexercise hypotension was not observed in centrally obese men, and resting SBP was not reduced after a short aerobic training program. Considerable individual variation in postexercise BP response among obese men may have implications for design of exercise interventions to lower BP in these individuals.
Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF
O’Brien, Emily C. , Holmes, DaJuanicia N. , Thomas, Laine , Kowey, Peter R. , Ansell, Jack , Piccini, Jonathan P. , Fonarow, Gregg C. , Mahaffey, Kenneth W. , Gersh, Bernard J. , Peterson, Eric D. , Hylek, Elaine M.

Mayo Clinic

Journal of the American Heart Association | June 9, 2018 | Volume: 7 | Issue: 12 | Pages: No page available

10.1161/jaha.117.006391 | PMID 29886422 Get It

Background Oral anticoagulation ( OAC ) reduces stroke risk in atrial fibrillation, but bleeding is a frequent side effect. The decision to discontinue or modify medication regimens in response to a bleeding event may differ according to bleeding site and severity. Methods and Results We used data from a large, national outpatient registry, ORBIT ‐ AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation; 2010–2011), to evaluate event characteristics and OAC management following the first bleeding event occurring during follow‐up. Bleeding events were classified into 3 categories: (1) International Society of Thrombosis and Hemostasis major bleeding, (2) clinically relevant nonmajor bleeding requiring medical attention, and (3) nuisance bleeding not requiring medical attention (eg, bruising, hemorrhoidal bleeding). Of 9743 patients enrolled in ORBIT ‐ AF with follow‐up data, 510 (3.23/100 subject‐years) experienced a major bleed, 615 (3.90/100 subject‐years), experienced a clinically relevant nonmajor bleed, and 1558 (9.87/100 subject‐years) experienced a nuisance bleed, among first bleeds over 2 years. Nearly one third of patients (31.6%) discontinued OAC therapy following a major bleeding event, 12.7% following a clinically relevant nonmajor bleed, and 4.5% following a nuisance bleed. Compared with those who experienced a clinically relevant nonmajor or nuisance bleed, patients who experienced a major bleed were more likely to be black and female and to have a history of heart failure and stroke. Those who discontinued were more likely to have central nervous system or gastrointestinal bleeding than those who persisted on OAC therapy. Conclusions Overall, 1 in 3 patients who experienced a major bleed was no longer anticoagulated after the event. Those who discontinued OAC were more likely to have central nervous system or gastrointestinal bleeding than those who persisted on OAC .
Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing
Mansfield, Aaron S. , Mullane, Michael P., Mansfield, Aaron S , Park, Ben Ho

Mayo Clinic

American Society of Clinical Oncology Educational Book | June 8, 2018 | Volume: No volume available | Issue: 38 | Pages: 873-880

10.1200/edbk_208339 | PMID 30231389 Get It

Many targeted therapies—and, more recently, immunotherapies—have been approved by the U.S. Food and Drug Administration (FDA) with companion diagnostic tests. Next-generation sequencing (NGS) platforms are now approved to screen for many of these abnormalities, and they are increasingly being applied to guide therapeutic decision-making outside of these intended uses. The results provided by NGS testing can vary significantly based on the exact test performed and the analysis of the sequencing data. Given the complexities associated with interpreting NGS test results and acting on them, academic and community molecular tumor boards have been developed to provide multidisciplinary expertise for this endeavor. NGS test results may identify FDA-approved therapies, guide clinical trial recommendations, or prompt consideration of expanded access to investigational agents or off-label use of therapies approved for other indications. Many clinical trials now include NGS testing to assign treatments to patients based on the molecular profiles of their tumors. Although NGS testing may eventually help realize the development of individualized treatment regimens based on combinations of targeted therapies, the use of unproven and nonapproved combinations can be toxic and expensive. Given the increasing reliance on genetic biomarkers to guide therapeutic recommendations for FDA-approved therapies or enrollment into clinical trials, NGS will remain an integral part of the evolving medical oncology practice.
Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice
Nassiri, Farhad, Coy, Shannon , Nejad, Romina , Zadeh, Gelareh , Santagata, Sandro , Galanis, Evanthia , Santagata, Sandro

Mayo Clinic

American Society of Clinical Oncology Educational Book | June 8, 2018 | Volume: No volume available | Issue: 38 | Pages: 148-157

10.1200/edbk_200989 | PMID 30231374 Get It

Important advances in our understanding of the molecular biology of brain tumors have resulted in a rapid evolution in the taxonomy of central nervous system (CNS) tumors, which culminated in the revised 2016 World Health Organization classification of CNS tumors that incorporates an integrated molecular/histologic diagnostic approach. Our expanding understanding of brain tumor genomics and molecular evolution during the disease course has started to impact clinical management. Furthermore, incorporation of genomic information in ongoing and planned neuro-oncology clinical trials is expected to lead to improved outcomes and result in personalized treatment options for patients with CNS malignancies.
Value and Cost of Myeloma Therapy—We Can Afford It
Hinkel, Jennifer M. , Hinkel, Jennifer, Fonseca, Rafaël

Mayo Clinic

American Society of Clinical Oncology Educational Book | June 8, 2018 | Volume: No volume available | Issue: 38 | Pages: 647-655

10.1200/edbk_200869 | PMID 30231366 Get It

A national conversation regarding the price and affordability of drugs exists, where concern for value and benefits of medications is challenged by the increasing price of both injectable and oral medications, including the cost of care of myeloma. At the same time, we have seen unprecedented improvements in the overall survival of patients with myeloma, mostly because of the availability of these new drugs. Here, we present data to assert that these medications and associated expenses are of direct benefit to patients and society. The entrepreneurial reward for drug development in the United States has fueled vigorous drug development efforts that have culminated in the approval of 11 new drugs for the treatment of myeloma by the U.S. Food and Drug Administration (FDA) since 1999. These patented drugs are available to patients in the United States usually at a higher price than in the rest of the world. Nevertheless, the majority of patients, via direct copay assistance or through indirect support via third parties, have access to these drugs irrespective of their socioeconomic status. One of the major regulatory hurdles that prevents access to these drugs is the legal impossibility that pharmaceutical companies have in directly supporting copay assistance for patients with government-funded health care. Moreover, assessments of value should include formal pharmacoeconomic analyses performed by experts. Interference with market forces and coercive action, such as price controls, or exercising eminent domain in the quest for cheaper medications will stymie innovation and rob us of the cures of the future.
Value and Cost of Myeloma Therapy
Rajkumar, S. Vincent

Mayo Clinic

American Society of Clinical Oncology Educational Book | June 8, 2018 | Volume: No volume available | Issue: 38 | Pages: 662-666

10.1200/edbk_200867 | PMID 30231405 Get It

Major advances have occurred in the treatment of multiple myeloma, including several new drugs that typically cost more than $100,000 per year. Although the gains in myeloma therapy improve overall survival considerably, they are available to only a fraction of the population of patients with myeloma in the world because of regulatory barriers and cost. Myeloma is an example of what is happening in cancer on a much larger scale. Many of the problems discussed call for a wider discussion across all cancers, but they are amplified in myeloma because of the need for multidrug regimens that combine three or more expensive new drugs for prolonged periods of time. In this article, the reasons for the high cost of cancer drugs and possible solutions are examined. The lack of correlation of value and price, the remarkable rise in prices of existing old medications over time, and the lack of access to lifesaving drugs across various countries are also discussed.
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer
Pegram, Mark D. , Zong, Yu , Yam, Clinton , Moulder, Stacy , Moulder, Stacy L. , Goetz, Matthew P.

Mayo Clinic

American Society of Clinical Oncology Educational Book | June 8, 2018 | Volume: No volume available | Issue: 38 | Pages: 65-77

10.1200/edbk_200715 | PMID 30231328 Get It

Metastatic breast cancer continues to be a life-threatening diagnosis that impacts hundreds of thousands of patients around the world. Targeted therapies are usually associated with less toxicity compared with cytotoxic chemotherapies and often induce response or durable disease control in estrogen receptor (ER) and/or HER2+ breast cancers. Drugs that target CDK 4/6 either alone or in combination with endocrine therapy have demonstrated substantial improvements in progression-free survival (PFS) compared with endocrine monotherapy. Most recently, PARP inhibitors have shown longer PFS compared with physician’s choice of chemotherapy in BRCA-associated cancers, leading to the first U.S. Food and Drug Administration (FDA) approval of a targeted therapy with the potential to benefit a subgroup of patients with triple-negative breast cancer (TNBC). Finally, newer drug delivery strategies using antibody drug conjugates have also allowed a “targeted approach” to deliver moderate to extremely potent cytotoxins directly to sites of metastatic disease, with less toxicity.
Updates in venous thromboembolism management: evidence published in 2017
Bartlett, Matthew , Bierle, Dennis M. , Saadiq, Rayya A. , Mauck, Karen F. , Daniels, Paul R. , Bartlett, Matthew A

Mayo Clinic

Hospital Practice | June 8, 2018 | Volume: 46 | Issue: 4 | Pages: 183-188

10.1080/21548331.2018.1486676 | PMID 29883230 Get It